Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy.
Vedanta Biosciences raises $106.5M for microbiome therapy
Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million. The funds will